Unlocking the potential of
genomic medicine

Overview



Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary01/04/2013
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 4, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that, on 2 January 2013 it
Toggle Summary01/30/2013
Phase I/II Study in Hepatitis C Expected to Provide Gateway to Hepatitis B and D MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Jan. 30, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company”), the developer of a novel platform technology for the sustained production and
Toggle Summary02/08/2013
MISGAV, Israel & SAN FRANCISCO --(BUSINESS WIRE)--Feb. 8, 2013-- Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the “Company” or “Medgenics”), the developer of a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using their own

Recent Presentations

More >>
Date Title
06/07/2018
03/28/2018
03/16/2018
08/10/2017
05/10/2017

Upcoming Events

More >>
Date Event Details
Summary Toggle 06/20/18 at 1:00 PM EDT

Aevi Genomic Medicine, Inc. at The 2018 JMP Securities Life Sciences Conference

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright Nasdaq. Minimum 15 minutes delayed.